Host-pathogen interplay in the respiratory environment of cystic fibrosis

Gibson, 2003, Pathophysiology and management of pulmonary infections in cystic fibrosis, Am J Respir Crit Care Med, 168, 918, 10.1164/rccm.200304-505SO Lipuma, 2010, The changing microbial epidemiology in cystic fibrosis, Clin Microbiol Rev, 23, 299, 10.1128/CMR.00068-09 Bevivino, 2013, The evolving polymicrobial composition in the airways of patients with cystic fibrosis: implications for disease progression and clinical management, CML – Cyst Fibros, 3, 93 Armstrong, 1997, Lower airway inflammation in infants and young children with cystic fibrosis, Am J Respir Crit Care Med, 156, 1197, 10.1164/ajrccm.156.4.96-11058 Kahl, 2010, Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease, Int J Med Microbiol, 300, 514, 10.1016/j.ijmm.2010.08.002 Beck, 2012, The microbiome of the lung, Transl Res, 160, 258, 10.1016/j.trsl.2012.02.005 Madan, 2012, Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures, MBio, 21, 4 Saiman, 2011, Infection prevention and control in cystic fibrosis, Curr Opin Infect Dis, 24, 390, 10.1097/QCO.0b013e32834748ff Cigana, 2011, Dampening host sensing and avoiding recognition in Pseudomonas aeruginosa pneumonia, J Biomed Biotechnol, 852513 Waters, 2011, Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease, Am J Respir Crit Care Med, 183, 635, 10.1164/rccm.201009-1392OC Tavs, 2014, Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis, Respir Res, 15, 41, 10.1186/1465-9921-15-41 Amin, 2010, The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis, Chest, 137, 171, 10.1378/chest.09-1103 Surette, 2014, The cystic fibrosis lung microbiome, Ann Am Thorac Soc, S61, 10.1513/AnnalsATS.201306-159MG Conrad, 2013, Cystic fibrosis therapy: a community ecology perspective, Am J Respir Cell Mol Biol, 48, 150, 10.1165/rcmb.2012-0059PS Brown, 2014, Directly sampling the lung of a young child with cystic fibrosis reveals diverse microbiota, Ann Am Thorac Soc, 11, 1049, 10.1513/AnnalsATS.201311-383OC Cox, 2010, Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients, PLoS One, 5, e11044, 10.1371/journal.pone.0011044 Zhao, 2012, Decade-long bacterial community dynamics in cystic fibrosis airways, Proc Natl Acad Sci U S A, 109, 5809, 10.1073/pnas.1120577109 Rieber, 2014, Current concepts of immune dysregulation in cystic fibrosis, Int J Biochem Cell Biol, 52, 108, 10.1016/j.biocel.2014.01.017 Button, 2012, A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia, Science, 337, 937, 10.1126/science.1223012 Boucher, 2007, Cystic fibrosis: a disease of vulnerability to airway surface dehydration, Trends Mol Med, 13, 231, 10.1016/j.molmed.2007.05.001 Skerrett, 2007, Redundant Toll-like receptor signaling in the pulmonary host response to Pseudomonas aeruginosa, Am J Physiol Lung Cell Mol Physiol, 292, L312, 10.1152/ajplung.00250.2006 Barnes, 1997, Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases, N Engl J Med, 336, 1066, 10.1056/NEJM199704103361506 John, 2010, TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells, Am J Respir Cell Mol Biol, 42, 424, 10.1165/rcmb.2008-0408OC Venkatakrishnan, 2000, Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells, Am J Respir Cell Mol Biol, 23, 396, 10.1165/ajrcmb.23.3.3949 Elizur, 2008, Airway inflammation in cystic fibrosis, Chest, 133, 489, 10.1378/chest.07-1631 Sagel, 2001, Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction, Am J Respir Crit Care Med, 164, 1425, 10.1164/ajrccm.164.8.2104075 Burns, 2003, Unique structural features that influence neutrophil emigration into the lung, Physiol Rev, 83, 309, 10.1152/physrev.00023.2002 Gaggar, 2008, A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation, J Immunol, 180, 5662, 10.4049/jimmunol.180.8.5662 Snelgrove, 2010, A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation, Science, 330, 90, 10.1126/science.1190594 Lämmermann, 2013, Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo, Nature, 498, 371, 10.1038/nature12175 Pazos, 2015, Distinct cellular sources of hepoxilin a3 and leukotriene b4 are used to coordinate bacterial-induced neutrophil transepithelial migration, J Immunol, 194, 1304, 10.4049/jimmunol.1402489 Bodini, 2005, Biomarkers of neutrophilic inflammation in exhaled air of cystic fibrosis children with bacterial airway infections, Pediatr Pulmonol, 40, 494, 10.1002/ppul.20336 Tamang, 2012, Hepoxilin A(3) facilitates neutrophilic breach of lipoxygenase-expressing airway epithelial barriers, J Immunol, 189, 4960, 10.4049/jimmunol.1201922 Hurley, 2008, Adhesion molecules involved in hepoxilin A3-mediated neutrophil transepithelial migration, Clin Exp Immunol, 151, 297, 10.1111/j.1365-2249.2007.03551.x Klesney-Tait, 2013, Transepithelial migration of neutrophils into the lung requires TREM-1, J Clin Invest, 123, 138, 10.1172/JCI64181 Sly, 2013, Risk factors for bronchiectasis in children with cystic fibrosis, N Engl J Med, 368, 1963, 10.1056/NEJMoa1301725 Gifford, 2014, The role of neutrophils in cystic fibrosis, Curr Opin Hematol, 21, 16, 10.1097/MOH.0000000000000009 Parsek, 2008, Pattern formation in Pseudomonas aeruginosa biofilms, Curr Opin Microbiol, 11, 560, 10.1016/j.mib.2008.09.015 Elias, 2012, Multi-species biofilms: living with friendly neighbors, FEMS Microbiol Rev, 36, 990, 10.1111/j.1574-6976.2012.00325.x Bjarnsholt, 2005, Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent, Microbiology, 151, 373, 10.1099/mic.0.27463-0 Donlan, 2002, Biofilms: survival mechanisms of clinically relevant microorganisms, Clin Microbiol Rev, 15, 167, 10.1128/CMR.15.2.167-193.2002 Chiang, 2013, Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms, Antimicrob Agents Chemother, 57, 2352, 10.1128/AAC.00001-13 Zimmermann, 2006, Induction of neutrophil chemotaxis by the quorum-sensing molecule N-(3-oxododecanoyl)-l-homoserine lactone, Infect Immun, 74, 5687, 10.1128/IAI.01940-05 Trevani, 2003, Bacterial DNA activates human neutrophils by a CpG-independent pathway, Eur J Immunol, 33, 3164, 10.1002/eji.200324334 Jesaitis, 2003, Compromised host defense on Pseudomonas aeruginosa biofilms: characterization of neutrophil and biofilm interactions, J Immunol, 171, 4329, 10.4049/jimmunol.171.8.4329 Jensen, 2007, Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa, Microbiology, 153, 1329, 10.1099/mic.0.2006/003863-0 Alhede, 2009, Pseudomonas aeruginosa recognizes and responds aggressively to the presence of polymorphonuclear leukocytes, Microbiology, 155, 3500, 10.1099/mic.0.031443-0 Walker, 2005, Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils, Infect Immun, 73, 3693, 10.1128/IAI.73.6.3693-3701.2005 Brinkmann, 2004, Neutrophil extracellular traps kill bacteria, Science, 303, 1532, 10.1126/science.1092385 Hakkim, 2011, Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation, Nat Chem Biol, 7, 75, 10.1038/nchembio.496 Fuchs, 2007, Novel cell death program leads to neutrophil extracellular traps, J Cell Biol, 176, 231, 10.1083/jcb.200606027 Farley, 2012, A serpinB1 regulatory mechanism is essential for restricting neutrophil extracellular trap generation, J Immunol, 189, 4574, 10.4049/jimmunol.1201167 Benarafa, 2007, The neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in Pseudomonas aeruginosa infection, J Exp Med, 204, 1901, 10.1084/jem.20070494 Yoo, 2014, NET formation induced by Pseudomonas aeruginosa cystic fibrosis isolates measured as release of myeloperoxidase-DNA and neutrophil elastase-DNA complexes, Immunol Lett, 160, 186, 10.1016/j.imlet.2014.03.003 Rada, 2013, Pyocyanin-enhanced neutrophil extracellular trap formation requires the NADPH oxidase, PLoS One, 8, e54205, 10.1371/journal.pone.0054205 Young, 2011, Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR, PLoS One, 6, e23637, 10.1371/journal.pone.0023637 Khatua, 2012, Sialoglycoproteins adsorbed by Pseudomonas aeruginosa facilitate their survival by impeding neutrophil extracellular trap through siglec-9, J Leukoc Biol, 91, 641, 10.1189/jlb.0511260 Thammavongsa, 2013, Staphylococcus aureus degrades neutrophil extracellular traps to promote immune cell death, Science, 342, 863, 10.1126/science.1242255 Langereis, 2013, Novel concepts in nontypeable Haemophilus influenzae biofilm formation, FEMS Microbiol Lett, 346, 81, 10.1111/1574-6968.12203 Rahman, 2014, Does NETosis contribute to the bacterial pathoadaptation in cystic fibrosis?, Front Immunol, 5, 378, 10.3389/fimmu.2014.00378 Hartl, 2012, Innate immunity in cystic fibrosis lung disease, J Cyst Fibros, 11, 363, 10.1016/j.jcf.2012.07.003 Del Porto, 2011, Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa, PLoS One, 6, e19970, 10.1371/journal.pone.0019970 Bruscia, 2009, Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/- mice, Am J Respir Cell Mol Biol, 40, 295, 10.1165/rcmb.2008-0170OC Di, 2006, CFTR regulates phagosome acidification in macrophages and alters bactericidal activity, Nat Cell Biol, 8, 933, 10.1038/ncb1456 Haggie, 2007, Cystic fibrosis transmembrane conductance regulator-independent phagosomal acidification in macrophages, J Biol Chem, 282, 31422, 10.1074/jbc.M705296200 Bruscia, 2011, Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis, J Immunol, 186, 6990, 10.4049/jimmunol.1100396 Bianchi, 2008, Impairment of apoptotic cell engulfment by pyocyanin, a toxic metabolite of Pseudomonas aeruginosa, Am J Respir Crit Care Med, 177, 35, 10.1164/rccm.200612-1804OC Dong, 1995, Activation of CFTR chloride current by nitric oxide in human T lymphocytes, EMBO J, 14, 2700, 10.1002/j.1460-2075.1995.tb07270.x Agarwal, 2012, Link between CFTR mutations and ABPA: a systematic review and meta-analysis, Mycoses, 55, 357, 10.1111/j.1439-0507.2011.02130.x Mueller, 2011, Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses, Am J Respir Cell Mol Biol, 44, 922, 10.1165/rcmb.2010-0224OC Knutsen, 2004, Increased sensitivity to IL-4 in cystic fibrosis patients with allergic bronchopulmonary aspergillosis, Allergy, 59, 81, 10.1046/j.1398-9995.2003.00129.x Moss, 2000, Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes, Clin Exp Immunol, 120, 518, 10.1046/j.1365-2249.2000.01232.x Cenci, 1999, Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses, J Infect Dis, 180, 1957, 10.1086/315142 Zelante, 2007, IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance, Eur J Immunol, 37, 2695, 10.1002/eji.200737409 Al Alam, 2010, Impaired interleukin-8 chemokine secretion by staphylococcus aureus-activated epithelium and T-cell chemotaxis in cystic fibrosis, Am J Respir Cell Mol Biol, 42, 644, 10.1165/rcmb.2008-0021OC Tiringer, 2013, A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection, Am J Respir Crit Care Med, 187, 621, 10.1164/rccm.201206-1150OC Hartl, 2006, Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis, J Allergy Clin Immunol, 117, 204, 10.1016/j.jaci.2005.09.023 Moser, 2000, The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type, APMIS, 108, 329, 10.1034/j.1600-0463.2000.d01-64.x Wojnarowski, 1999, Cytokine expression in bronchial biopsies of cystic fibrosis patients with and without acute exacerbation, 14, 1136 Moser, 2002, Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response, Clin Exp Immunol, 127, 206, 10.1046/j.1365-2249.2002.01731.x Decraene, 2010, Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable cystic fibrosis patients, Respir Res, 11, 177, 10.1186/1465-9921-11-177 Chan, 2013, Patients with cystic fibrosis have inducible IL-17+IL-22+ memory cells in lung draining lymph nodes, J Allergy Clin Immunol, 131, 1117, 10.1016/j.jaci.2012.05.036 Amin, 2010, Secretory immunoglobulin A abrogates inflammatory responses and improves mortality after Pseudomonas pneumonia, J Trauma, 68, 827, 10.1097/TA.0b013e3181d486fe Doring, 2007, A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients, Proc Natl Acad Sci U S A, 104, 11020, 10.1073/pnas.0702403104 Johansen, 2013, Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis, Cochrane Database Syst Rev, 6, CD001399 Fuxman Bass, 2010, Extracellular DNA: a major proinflammatory component of Pseudomonas aeruginosa biofilms, J Immunol, 184, 6386, 10.4049/jimmunol.0901640 Konstan, 2003, Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects, J Pharmacol Exp Ther, 306, 1086, 10.1124/jpet.103.052449 Lands, 2007, Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis, Cochrane Database Syst Rev, 4, CD001505 Bertolotto, 2014, Neutrophil migration towards C5a and CXCL8 is prevented by non-steroidal anti-inflammatory drugs via inhibition of different pathways, Br J Pharmacol, 171, 3376, 10.1111/bph.12670 Saiman, 2003, Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial, JAMA, 290, 1749, 10.1001/jama.290.13.1749 Drago, 2013, Activity of N-acetyl-l-cysteine against biofilm of Staphylococcus aureus and Pseudomonas aeruginosa on orthopedic prosthetic materials, Int J Artif Organs, 36, 39, 10.5301/ijao.5000135 Sprenger, 2011, Dexamethasone and N-acetyl-cysteine attenuate Pseudomonas aeruginosa-induced mucus expression in human airways, Pulm Pharmacol Ther, 24, 232, 10.1016/j.pupt.2010.11.003 Kirchner, 2013, Flavonoids and 5-aminosalicylic acid inhibit the formation of neutrophil extracellular traps, Mediators Inflamm, 2013, 710239, 10.1155/2013/710239 Conrad, 2014, Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial, J Cyst Fibros van Overveld, 2003, Inhibitory capacity of different steroids on neutrophil migration across a bilayer of endothelial and bronchial epithelial cells, Eur J Pharmacol, 477, 261, 10.1016/S0014-2999(03)02153-8 Eigen, 1995, A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group, J Pediatr, 126, 515, 10.1016/S0022-3476(95)70343-8 Flume, 2007, Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health, Am J Respir Crit Care Med, 176, 957, 10.1164/rccm.200705-664OC Konstan, 2014, A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis, J Cyst Fibros, 13, 148, 10.1016/j.jcf.2013.12.009 Doring, 2014, BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs, J Cyst Fibros, 13, 156, 10.1016/j.jcf.2013.10.007 Pott, 2013, Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells, Front Public Health, 1, 19, 10.3389/fpubh.2013.00019 Martin, 2006, Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis, Pediatr Pulmonol, 41, 177, 10.1002/ppul.20345 Francois, 2012, Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial, Crit Care Med, 40, 2320, 10.1097/CCM.0b013e31825334f6 Milla, 2014, Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection, Pediatr Pulmonol, 49, 650, 10.1002/ppul.22890